About Us
Aptagen, LLC is a global leader in aptamer development with over 25 years of experience generating high affinity and specifically-binding aptamers for small molecules, proteins, cells, and tissues. We produce state-of-the-art target-recognition elements for diagnostics, therapeutics, and bio-industrial applications.
Aptagen has grown from a one-man operation with the ingenuity and support of interns, graduate students, and post-docs to a tight-knit developing business with a world-class team of scientists, servicing clients ranging globally from research academics at top-tier institutions to BigPharma companies. Aptagen was named as a finalist for the “Top Emerging Business of the Year” of 2011 by Central Penn Business Journal. Aptamers are an emerging technology that is poised to become the next evolution in diagnostics and drug discovery. Aptagen continues to play a leading role in developing aptamer technology that will assist in the treatment and diagnosis of various diseases. Today, Aptagen is a leader in the field of aptamers and has a strong reputation for “Taking on Challenging Projects, and Delivering Positive Results.”Aptagen was formed in 2004, and operations began two years later in 2006. Aptagen is located in Jacobus, PA, a suburb of York, beautifully surrounded by hiking and horseback riding trails near Lake Williams and Lake Redman. We are conveniently situated off of Interstate 83. The facility is a forty-minute drive from Johns Hopkins University and Hershey Medical Center.
Aptagen Interns
Aptagen’s Executive Summary
Aptagen is a biotechnology company offering aptamer products and services as reagents, diagnostic and biomarker discovery tools, as well as for use in drug discovery, targeted delivery for therapeutics, and bioindustrial applications.
Aptagen develops and manufactures aptamers (ligands of RNA, DNA, and peptide oligonucleotides that bind to a variety of target antigens). Aptamers are sometimes referred to as “chemical antibodies or DNA antibodies.” Aptazymes are aptamers with enzymatic activity. A subclass of aptazymes called molecular switches is analogous to molecular beacons for fluorescent detection of analytes in test samples. Examples include allosteric ribozymes, also known as riboswitches.
Aptagen’s business plan is a dual approach to replacing the current technology being utilized. The retail arm of Aptagen provides customers with an industry first “Apta-Index™” that offers a low-cost service for synthesizing known aptamers (synthetic antibodies) for research and development purposes. The R&D arm of Aptagen has a primary objective to provide a customized service for drug development and therapeutic applications through long-term, large dollar contracts.
The problem: Current technology is outdated. Antibodies were discovered in the 1890’s and have been the primary biotechnology research vehicle for the last one hundred and ten years. The antibody method involves multiple trial and error experiments that result in extremely high development cost and is only 20% successful on average. Aptamers (synthetic antibodies) were developed in the 1990’s and have been increasingly gaining in popularity and availability over the last ten years. The lower manufacturing costs and the near-endless applicability is solidifying aptamers (synthetic antibodies) as the next evolution of drug discovery and diagnostics.
Because aptamers (synthetic antibodies) are an in-vivo (directly tested in the animal model) approach, they avoid the majority of the bench testing, saving several years and approximately 35% of the R&D cost. The unique chemistry of aptamers, unlike other forms of drugs currently used, permits the natural selection of drug candidates in whole animal models, bypassing the test tube entirely. By using an animal model with the disease state of interest, Aptagen need not possess specific knowledge of the pathology or disease condition in question. As an added benefit, because this approach reduces the false starts, there are actually fewer animals needed for drug evaluation.